Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Has Consensus Price Target of $9.40 According to Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $9.40.

Several research firms have recently weighed in on TVRD. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a report on Wednesday, July 8th. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. Finally, BTIG Research reduced their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth about $34,000. Susquehanna International Group LLP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $63,000. Finally, BlackRock Inc. acquired a new stake in Tvardi Therapeutics in the second quarter valued at $181,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Price Performance

Tvardi Therapeutics stock opened at $1.07 on Tuesday. Tvardi Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $7.23. The stock has a 50-day simple moving average of $1.58 and a 200-day simple moving average of $2.49.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, research analysts anticipate that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.